One of the primary roles for any Big Pharma CEO is to act as a chief defender of the pipeline. Just months ago, Chris Viehbacher boldly asserted that Sanofi had one of the top 5 pipelines in the industry, if you added in some top programs among its close development partners.
Development of a vaccine to protect against the Escherichia coli (E. coli) bacterium has been stymied because the genetic structure of the many strains of E. coli varied hugely. But according to a new study, the diversity of E. coli 's numerous strains is not as vast as previously thought, inspiring hopes that a global vaccine can be developed.
Eye care company Ocular Therapeutix today announced the results of its Phase II trial of its Sustained Release Dexamethasone aimed at treating allergic conjunctivitis. The 42-day randomized, double-blind study of 68 patients showed that patients on the candidate had lower ocular itching and conjunctival redness scores than those on the placebo, the company said.
HIV/AIDS prevention can be difficult in countries with limited resources, especially when it comes to the millions of affected children who are less likely to tolerate antiretroviral drugs. In an effort to overcome this challenge, researchers at Penn State University have developed a delivery system for the antiretroviral Ritonavir that uses a protein in cow's milk for oral administration of the drug.
Fujifilm is confident its recently approved flu treatment can combat the spread of ebolavirus in West Africa, preparing for a surge in manufacturing as it waits on clinical trial results.
RNA interference specialist Arrowhead presented new data from an ongoing Phase IIa study of its hepatitis B treatment ARC-520, demonstrating a reduction of the disease's surface antigens in what the company says is a first for RNAi.
Just a few weeks after claiming success with a pair of late-stage studies of its prolonged dosing approach to diabetes, Boston-based Intarcia has followed up with a billion dollar-plus sized commercialization deal for ex-U.S. and Japan commercial rights with France's Servier.
Scientists from Nevada's Roseman University of Health Sciences presented their work on a nasal spray formulation of the antipsychotic prochlorperazine for the treatment of migraines at the American Association of Pharmaceutical Scientists annual meeting in San Diego.
The growing scourge of liver disease in the developed world has spurred a frenzied race among drug developers to ferret out new therapies, and Takeda, new to the field, has recruited the diagnostics experts at GE Healthcare to shepherd its early R&D efforts.
As the med tech industry casts its eye toward wearable, non-invasive devices to elevate mood, startup Thync is developing a smartphone-connected product that boosts users' mood by stimulating nerves in the head.